Editorial: Resection and survival

Restricted access

If the inline PDF is not rendering correctly, you can download the PDF file here.

Article Information

Please include this information when citing this paper: published online March 16, 2012; DOI: 10.3171/2011.10.JNS111437.

© AANS, except where prohibited by US copyright law.

Headings

References

  • 1

    Brandes AATosoni ASpagnolli FFrezza GLeonardi MCalbucci F: Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: pitfalls in neurooncology. Neuro Oncol 10:3613672008

  • 2

    Brandsma DStalpers LTaal WSminia Pvan den Bent MJ: Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 9:4534612008

  • 3

    Clarke LPVelthuizen RPCamacho MAHeine JJVaidyanathan MHall LO: MRI segmentation: methods and applications. Magn Reson Imaging 13:3433681995

  • 4

    Clarke LPVelthuizen RPClark MGaviria JHall LGoldgof D: MRI measurement of brain tumor response: comparison of visual metric and automatic segmentation. Magn Reson Imaging 16:2712791998

  • 5

    Dempsey MFCondon BRHadley DM: Measurement of tumor “size” in recurrent malignant glioma: 1D, 2D, or 3D?. AJNR Am J Neuroradiol 26:7707762005

  • 6

    Friedman HSPrados MDWen PYMikkelsen TSchiff DAbrey LE: Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27:473347402009

  • 7

    Jaffe CC: Measures of response: RECIST, WHO, and new alternatives. J Clin Oncol 24:324532512006

  • 8

    Joe BNFukui MBMeltzer CCHuang QSDay RSGreer PJ: Brain tumor volume measurement: comparison of manual and semiautomated methods. Radiology 212:8118161999

  • 9

    Kanaly CWDing DMehta AIWaller AFCrocker IDesjardins A: A novel method for volumetric MRI response assessment of enhancing brain tumors. PLoS One 6:e160312011

  • 10

    Macdonald DRCascino TLSchold SC JrCairncross JG: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:127712801990

  • 11

    Moonis GLiu JUdupa JKHackney DB: Estimation of tumor volume with fuzzy-connectedness segmentation of MR images. AJNR Am J Neuroradiol 23:3563632002

  • 12

    Pham DLXu CPrince JL: Current methods in medical image segmentation. Annu Rev Biomed Eng 2:3153372000

  • 13

    Polley MYLamborn KRChang SMButowski NClarke JLPrados M: Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomide. Neuro Oncol 12:2742822010

  • 14

    Reardon DAGalanis EDeGroot JFCloughesy TFWefel JSLamborn KR: Clinical trial end points for high-grade glioma: the evolving landscape. Neuro Oncol 13:3533612011

  • 15

    Sankar TMoore NZJohnson JAshby LSScheck ACShapiro WR: Magnetic resonance imaging volumetric assessment of the extent of contrast enhancement and resection in oligodendroglial tumors. Clinical article. J Neurosurg [epub ahead of print March 16 2012. DOI: 10.3171/2012.2.JNS102032]

  • 16

    Shah GDKesari SXu RBatchelor TTO'Neill AMHochberg FH: Comparison of linear and volumetric criteria in assessing tumor response in adult high-grade gliomas. Neuro Oncol 8:38462006

  • 17

    Therasse PArbuck SGEisenhauer EAWanders JKaplan RSRubinstein L: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:2052162000

  • 18

    Vaidyanathan MClarke LPHall LOHeidtman CVelthuizen RGosche K: Monitoring brain tumor response to therapy using MRI segmentation. Magn Reson Imaging 15:3233341997

  • 19

    van den Bent MJVogelbaum MAWen PYMacdonald DRChang SM: End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's Criteria. J Clin Oncol 27:290529082009

  • 20

    Wen PYMacdonald DRReardon DACloughesy TFSorensen AGGalanis E: Updated response assessment criteria for high-grade gliomas: response assessment in neurooncology working group. J Clin Oncol 28:196319722010

  • 21

    Wu WLamborn KRBuckner JCNovotny PJChang SMO'Fallon JR: Joint NCCTG and NABTC prognostic factors analysis for high-grade recurrent glioma. Neuro Oncol 12:1641722010

  • 1

    Jaffe CC: Measures of response: RECIST, WHO, and new alternatives. J Clin Oncol 24:324532512006

  • 2

    Macdonald DRCascino TLSchold SC JrCairncross JG: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:127712801990

  • 3

    Sanai NPolley MYMcDermott MWParsa ATBerger MS: An extent of resection threshold for newly diagnosed glioblastomas. Clinical article. J Neurosurg 115:382011

  • 4

    Sled JGZijdenbos APEvans AC: A nonparametric method for automatic correction of intensity nonuniformity in MRI data. IEEE Trans Med Imaging 17:87971998

TrendMD

Metrics

Metrics

All Time Past Year Past 30 Days
Abstract Views 76 76 7
Full Text Views 72 72 2
PDF Downloads 69 69 5
EPUB Downloads 0 0 0

PubMed

Google Scholar